Editorial Board member, Bernardo Rapoport discusses neoadjuvant breast cancer at the ASCO 2019 annual meeting. Considering data presented at the meeting he also reviews the unmet needs, what factors influence treatment in this population and how to overcome current treatment challenges.
Questions
1. What are the major unmet needs in the neoadjuvant treatment of breast cancer? (0:04)
2. What factors influence the decision to give neoadjuvant treatment? (2:20)
3. What are the challenges of assessing response to neoadjuvant therapies and how can these be overcome? (3:06)
4. Could you tell us about the latest data on trastuzumab emtansine in the neoadjuvant treatment of HER2-positive breast cancer? (4:08)
5. What presentations on neoadjuvant breast cancer are you most interested in at this year’s meeting? (5:59)
Speaker disclosure: Bernardo Rapoport has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
